Daily filing brief

10 Most Important Filings — 9 August 2026

A concise list of today's most consequential exchange filings, selected for relevance and impact.

  1. Gland Pharma Ltd3:02 pm IST

    Gland Pharma Announces Strategic CDMO Manufacturing Agreement with Global Pharmaceutical Company

    Deal overview

    • Strategic CDMO partnership with a global pharma company; Manufacturing and Supply Agreement for sterile injectables.

    Scope and offerings

    • 55 SKUs across three sites; technology transfer, development, and long-term supply.

    One-stop CDMO solution

    • Integrated development, technology transfer, manufacturing, and regulatory support for partner.

    Financial outlook

    • Annual revenue potential of USD 90-100 million post-commercialization.

    Timeline

    • Technology transfer expected within two years; revenues from calendar year 2029.

    Strategic rationale

    • Strengthens Gland Pharma's position as an end-to-end sterile injectables CDMO.
    Read the original filing
  2. DOMS Industries Ltd5:54 pm IST

    DOMS Industries Q1 FY27: Revenue up 19.2% to INR670 crores; margins pressured by RM volatility; Reynolds integration and 50-acre capex underway; guidance 18-20% growth

    Financial Performance

    • Revenue rose 19.2% to INR670 crores in Q1 FY27.
    • EBITDA fell 16.4% to INR82.6 crores; margin 12.3%.
    • PAT declined to INR45.3 crores; PAT margin 6.8%.
    • Gross margins declined about 400 basis points due to raw material inflation.
    • ESOP-related costs and channel-partner events reduced margins by ~0.4 percentage points.

    Capacity Expansion and Reynolds Integration

    • 50+ acre greenfield project development is on track; commissioning ~300,000 sq ft by Q2 FY27.
    • Invested close to INR100 crores in Q1 FY27 toward capital investments.
    • Reynolds asset acquisition completed; Umbergaon asset movement completed; full sales potential unlocked over time.
    • Reynolds had about INR130-140 crores revenue in the previous year.
    • Reynolds to operate in parallel; capacity growth will come from planned expansions, not extra volumes.
    • Target ASP uplift from Reynolds; some capacity diverted to Reynolds products.
    • Plans to launch diaries and paper stationery under Reynolds.

    Guidance and Outlook

    • Guidance remains 18-20% consolidated sales growth; margin visibility limited due to RM volatility.
    • No further price hikes planned in the current quarter.
    • FY28 margin target around mid-teens; requires RM normalization.
    • Capex cadence discussed; annual plan around INR200-250 crores; execution space constraints.

    Pricing and Margin Dynamics

    • Average price rise in Q1 was 4-5%.
    • Average RM price increase was about 20% with 10-11% consumption growth.
    • About 500 bps of pass-through remains to be captured.
    • Current quarter not planning further price hikes; volatility to settle before decisions.
    • Management will add value to products without sacrificing margins.

    Exports and Geography

    • Export growth was flat in Q1 FY27; headwinds.
    • Exports contribute about 12% of revenue.
    • West Asia disruptions caused longer transit times and higher freight.
    • West India revenue declined to about INR140 crores YoY from INR186 crores.

    Operations and Capital Allocation

    • 3x sales per INR invested; historically around 2.7x last year.
    • 18-24 months to reach full production capacity.
    • Jammu site added 11+ acres; additional land acquisitions.
    • 50-acre plant and adjacent expansions to serve both brands.

    Q&A Highlights

    • Margin trajectory discussed; pricing calibrated to protect market share.
    • Reynolds is brand expansion with ASP uplift but limited volume growth.
    • Industry pricing aligned with peers; no aggressive hikes.
    • ESOP costs for FY27 ~INR10 crores; may rise in FY28.
    Read the original filing
  3. Quality Power Electrical Equipments Ltd6:58 pm IST

    Quality Power Q1 FY2027 revenue up 32% to ₹2,564 million; order book ₹19,455 million and expansion plans disclosed

    Financial highlights

    • Total revenue for Q1 FY2027: ₹2,564 million, up 32.1% YoY.
    • Adjusted EBITDA: ₹725 million; margin 28.3%.
    • Profit after tax (adjusted): ₹545 million; margin 21.3%.
    • Reported PBT ₹594 million; PAT ₹467 million.
    • Order book ₹19,455 million; ~1.9x FY2026 revenue.
    • Interim dividend declared for FY2027: ₹0.25 per equity share.
    • Proposed acquisition of Winwin Speciality Insulators Limited progressing; EV ~₹315 crore.
    • Sangli manufacturing expansion on track; trial production targeted August 2026.
    • Endoks Turkey expansion: civil work complete; interior fit-out; European operations start Q3 FY2027.
    • HVDC CTC magnet wire facility: machinery installation to commence August 2026.
    • Appointment of Shylendra Kumar as Group CTO.
    • Ind AS 29 adjustment: ₹78.21 million net monetary loss; adjusted measures presented.
    • Order book by subsidiary: Endoks ₹8,010 Mn; Mehru ₹5,850 Mn; Quality Power ₹5,530 Mn.

    Strategic developments

    • Winwin Speciality Insulators acquisition: term sheet executed June 2026; EV ~₹315 crore.
    • Q1 order wins: US data centre HV reactors; Japan FACTS system; India instrument transformers.
    • Endoks Turkey expansion: civil complete; interior fit-out; European operations start Q3 FY2027.
    • Sangli manufacturing expansion: machinery installation underway; trial production August 2026.
    • HVDC magnet wire facility: machinery installation to commence August 2026.
    • Shylendra Kumar appointed Group CTO.
    • Interim dividend: ₹0.25 per share.

    Outlook and execution

    • Outlook: robust long-term demand for grid modernization and energy transition.
    • Execution and supply chain resilience remain priority amid raw material constraints.
    Read the original filing
  4. Sky Gold And Diamonds Ltd5:50 pm IST

    Sky Gold and Diamonds reports Q1 FY27 standalone and consolidated results; subsidiary fraud disclosed

    Standalone results

    • Standalone revenue from operations: Rs 1,44,004.43 lakh.
    • Standalone total income: Rs 1,44,692.05 lakh.
    • Standalone PBT: Rs 8,180.32 lakh.
    • Standalone PAT: Rs 6,058.76 lakh.
    • Standalone EPS: Basic Rs 3.91; Diluted Rs 3.91.
    • Standalone India revenue: Rs 1,23,072.92 lakh.
    • Standalone outside India revenue: Rs 20,931.51 lakh.
    • Standalone results reviewed by statutory auditors with unmodified opinion.
    • Board approved standalone results on 9 August 2026.
    • Single operating segment: gold jewellery.

    Consolidated results

    • Consolidated revenue from operations: Rs 2,01,279.39 lakh.
    • Consolidated total income: Rs 2,02,074.77 lakh.
    • Consolidated PBT: Rs 13,480.33 lakh.
    • Consolidated PAT: Rs 10,490.19 lakh.
    • Consolidated EPS: Basic Rs 6.67; Diluted Rs 6.66.
    • Consolidated India revenue: Rs 1,63,694.26 lakh.
    • Consolidated outside India revenue: Rs 37,585.13 lakh.
    • Consolidated results reviewed by statutory auditors with unmodified opinion.
    • Group operates a single segment: gold jewellery.

    Post-quarter event

    • Fraud incident at Starmangalsutra Private Limited caused up to Rs 1,070.00 lakh loss.
    • Investigation ongoing; cyber fraud involved unauthorized transfers.
    • Measures to strengthen employee awareness, verification procedures and internal controls implemented.
    Read the original filing
  5. IDFC First Bank Ltd5:31 am IST

    IDFC FIRST Bank Integrated Annual Report FY2025-26 – Investor Highlights

    Financial Performance

    • Total consolidated income ₹48,422.39 crore.
    • Consolidated PAT ₹1,610 crore.
    • Loans and advances ₹2.84 lakh crore, up 20% YoY.
    • Deposits ₹2.94 lakh crore.

    Capital & Capital Adequacy

    • CAR 15.05%.
    • CET1 13.33%.

    Dividend & Corporate Actions

    • Proposed dividend ₹0.25 per equity share.
    • Amalgamation of eIDFC into Bank effective Oct 1, 2024.

    Additional Capital Actions

    • Equity raise up to ₹7,500 crore.
    • Debt issuance up to ₹12,500 crore.
    Read the original filing
  6. Deepak Fertilisers & Petrochemicals Corporation Ltd10:44 pm IST

    Deepak Fertilisers & Petrochemicals FY2025-26 Annual Report: Strength at the Core, Value Built to Soar

    Financial performance

    • Consolidated revenue from operations: ₹11,506 crore, up 12% YoY.
    • Operating EBITDA: ₹1,684 crore; Profit after tax: ₹739 crore.
    • PAT margin: 6.4%; EBITDA margin: 14.6% (consolidated).
    • Net debt to equity: 0.67x; DSCR: 1.12x.
    • Consolidated earnings per share: ₹58.40; ROE declined vs prior year.
    • Operating cash flow supported by disciplined working capital management.

    Growth & strategy

    • Transforming from a products company to a solutions platform across CNB, IC, and Mining.
    • Investing in capacity, backward integration, digitalisation, and supply-chain resilience.
    • Key acquisitions to strengthen mining solutions: Chardham Chemicals and 100% PBS platforms.
    • LNG-to-ammonia integration and TAN/N nitric acid expansions to enhance margin resilience.
    • Strategic LNG regasification and novation of LNG supply with Equinor to DGPL.

    Key projects & capacity

    • Gopalpur TAN: 376 KTPA; ~95% complete; commissioning expected H2 FY2026-27.
    • Dahej Nitric Acid expansion: WNA 300 KTPA, CNA 150 KTPA; ~86% complete.
    • Post-commissioning, Group TAN capacity ~1 MTPA, addressing ~60% of domestic TAN demand.
    • Dahej CN A expansion to support broader downstream nitration and mining needs.
    • Two flagship projects approach commissioning to translate capex into volumes and earnings.

    Capital structure & liquidity

    • Net debt in FY2025-26: ₹4,99,001 lakh; gearing 0.67x.
    • Bank borrowings: total facilities used ₹4,117 crore; unused ₹1,281 crore.
    • WC facilities used ₹902 crore; unused ₹1,544 crore.
    • CCDs of ₹80,000 lakh issued by DMSL; equity component recognised in OCI/NCI.
    • End-FY liquidity supported by ₹37,771 lakh cash & cash equivalents.

    Governance & ESG

    • Dr Purvi Mehta Bhatt appointed Independent Woman Director (from Jan 1, 2026).
    • Yeshil Sailesh Mehta appointed Non-Executive Non-Independent Director (from Jul 1, 2026).
    • IsFon CSR: 63,076 beneficiaries; CSR spend ₹327.27 lakh; shortfall ₹419 lakh carried forward.
    • CSR shifted from Skill Development Centre to Centre of Excellence; governance and policy disclosures on company site.
    • NFRA/secretarial audits; robust internal controls; board committees active with regular oversight.

    Dividend & shareholder matters

    • Forty-sixth AGM on 1 Sept 2026 via VC/OAVM; e-voting enabled.
    • Dividend proposed: ₹10 per equity share (face value ₹10); payout date on or before 30 Sept 2026.
    • Share dematerialisation: ~97.75% of shares in demat form; benefit from faster trading.
    • Unclaimed dividends/shares as per IEPF framework; claim window and process detailed in annual report.

    Risks & outlook

    • Global macro: IMF/IMF-linked trends; India growth supports chemicals, mining, and agri inputs.
    • Raw material volatility and energy costs; potential subsidy and policy shifts in fertilisers.
    • Geopolitical tensions and supply-chain disruptions; currency/commodity price fluctuations.
    • Execution risk on large capex (TAN/NA) and integration of acquisitions; regulatory approvals timing.
    Read the original filing
  7. Medi Assist Healthcare Services Ltd1:46 am IST

    Medi Assist Q1 FY27: Revenue Up 24.1%; Paramount Integration Near Closure; AI Contracts Signed; International Platform Established

    Financial Highlights

    • Operating revenue ₹236.5 Cr, +24.1% YoY.
    • EBITDA ₹48.0 Cr, 20.3% margin; down 175 bps YoY.
    • Reported PAT ₹27.6 Cr, 11.2% margin; +21.9% YoY.
    • Adjusted PAT ₹24.5 Cr; +8.2%.
    • India Health PUM ₹8,975 Cr, +26.8% YoY.
    • Group market share 37.6%; +440 bps YoY.
    • Technology revenue ₹7.8 Cr, +55.5% YoY.
    • Free Cash ₹245.5 Cr (C&CE).
    • Debt-free balance sheet.

    Strategic & Operational Developments

    • Paramount integration at logical close; 95%+ group claims migrated.
    • AI platform contracts signed with seven insurers.
    • Mayfair ownership 91.75%; international platform established.
    • Thailand first tech deployment live from 1 July 2026.
    • Nikhil Chopra appointed to lead international business full-time.
    • Q1 international revenue ₹10.1 Cr; -5.2% YoY.

    Governance Changes

    • Dr. Vikram Jit Singh Chhatwal becomes Non-Executive, Non-Independent Director and Chairman.
    • Gaurav Bhatnagar appointed Chief TPA Officer; designated SMP.

    Outlook & Financial Position

    • Q2 FY27 to run three active tracks.
    • Tech licensing and international platforms to improve EBITDA margins.
    • Growth funded entirely from operating cash flows; no external capital.
    • Contract liabilities ₹337.4 Cr at 30 Jun 2026.
    • Balance sheet snapshot: Debt-free; Net worth ₹884.1 Cr as of 30 Jun 2026.
    Read the original filing
  8. Sky Gold And Diamonds Ltd6:53 pm IST

    Sky Gold and Diamonds reports Q1 FY27 revenue growth; appoints CEO; raises FY27 guidance

    Business Overview

    • Core business: lightweight gold and diamond jewellery for B2B retailers.
    • Exports focus with London expo; initial UK/Europe orders ₹30–45 cr.
    • Advance Gold model reduces working capital; target ~30% volumes by FY30.
    • Vision 2030 Sky Gold 3.0 prioritizes cash generation and governance.

    Financial Performance

    • Q1 FY27 revenue ₹2,012.8 cr; YoY +77.9%.
    • Q1 FY27 EBITDA ₹156.7 cr; margin 7.8%.
    • Q1 FY27 PAT ₹104.9 cr; margin 5.2%.
    • FY26 revenue ₹6,294.9 cr; EBITDA ₹434.3 cr; PAT ₹281.8 cr.
    • FY27 guidance: revenue ₹8,100 cr; EBITDA margin 7.0–7.5%; PAT margin 4.5–4.75%.

    Operational Highlights

    • Appointed Akash Talesara as CEO.
    • Showcased at Asiana UK-India Expo, London; initial orders ₹30–45 cr.
    • Value-added share rose to 50–55% in FY26, driving margin expansion.
    • Advance Gold volumes ~30% by FY30; zero working capital inventory.
    • Manufacturing footprint expanded to 135,000 sq ft; Dubai office opened; MSKA appointed.

    Capital Structure & Liquidity

    • Total equity as of 31-Mar-26: ₹1,205.9 cr; share capital ₹154.9 cr.
    • Total assets ₹2,195.2 cr; current assets ₹1,636.1 cr.
    • Total borrowings ₹847.9 cr (non-current ₹48.1 cr; current ₹799.8 cr).
    • Cash and cash equivalents ₹7.9 cr; net current assets ~₹712.5 cr.
    • Operating cash flow FY26: ₹44.9 cr negative; financing cash flow ₹171.0 cr.

    Strategic Priorities & Outlook

    • FY30 guidance: revenue ₹18,000–₹19,000 cr; PAT margin ~5.25%+; ROCE 27%+.
    • Growth drivers: higher export mix, value-added jewellery, and advanced gold adoption.
    • FY27 guidance revised upwards; focus on margin expansion and capital efficiency.
    • Dubai expansion and new geographies to broaden export footprint.

    Governance & Leadership

    • Promoters adopt dividend-only compensation; no salaries from FY27.
    • MSKA & Associates LLP appointed as Statutory Auditors.
    • Onboarded BDO for enhanced financial reporting and governance.
    • Board strengthened with industry veterans; leadership hires across domains.
    • CEO appointment: Akash Talesara; background in gems and jewellery.
    Read the original filing
  9. Kwality Pharmaceuticals Ltd4:58 am IST

    Kwality Pharmaceuticals Limited — Annual Report 2025-26 overview for investors

    Financial performance

    • Standalone revenue from operations ₹503.06 crore; Consolidated ₹503.08 crore.
    • PAT ₹67.35 crore; up from ₹39.89 crore last year.
    • EBITDA margin 19.97%; net profit margin 13.39%.
    • PBT ₹89.49 crore; PAT growth ~68.8% YoY.
    • Dividend not declared for FY26.
    • Net cash from operations ₹16.60 crore; investing ₹34.91 crore.
    • Financing cash flow ₹7.04 crore; overall cash decreased ₹11.28 crore.
    • DSIR-recognized in-house R&D; ₹60 lakh invested; 40+ BE molecules; three monoclonal antibodies.
    • FY27 guidance raised to >₹700 crore; long-term target ₹1,000 crore by FY29.
    • EPS ₹64.90; ROE benefited by higher profitability.

    Operations & strategy

    • Single pharmaceutical-formulations segment; 1,000+ products across 25+ therapies.
    • Global footprint: 70+ countries; EU-GMP approved manufacturing; 5 facilities; Unit 6 hormones under construction.
    • Bioequivalence program spanning 40+ oral solid molecules; three monoclonal antibodies in development.
    • Erythropoietin (Kwalipoietin) BE program pre-clinical done; track for CY2027 launch subject to approvals.
    • Significant regulatory audits completed; focus on enhanced regulatory readiness.
    • Exhibited presence at 15+ global pharma events to deepen direct customers.
    • Strategic capex on hormone facility and oncology/biologics capacity expansion; automation upgrades.

    Capital structure & liquidity

    • Standalone equity ₹333.37 crore; Consolidated equity ₹329.92 crore.
    • Share capital ₹10.38 crore; no change in paid-up capital FY26.
    • Long-term borrowings ₹29.40 crore; short-term borrowings ₹101.06 crore.
    • Debt-equity ratio ~0.40; interest coverage 9.15x; operating margin 19.97%; net margin 13.39%.
    • Current ratio 1.80; cash and cash equivalents ₹0.74 crore.
    • Africa subsidiary Kwality Africa Limitada: 51% held; turnover small; year-end loss.

    Governance & risk

    • Independent director Swanith Kapoor appointed June 2, 2026; term five years.
    • Resignations: Kiran Kumar Verma (July 26, 2025); Kartik Kapur (June 2, 2026); Pankaj Takkar and Ravi Shanker Singh.
    • Board meetings held: 12; Audit Committee meetings: 5; Nomination & Remuneration: 4; CSR: 1.
    • Audit Committee chair changed to Bhavesh Mahajan from Feb 1, 2026; KMP changes noted.
    • Secretarial audit by M/s Rishi Mittal & Associates; no qualifications reported.
    • Risk management framework in place; ongoing monitoring of regulatory, product, and FX risks.

    Dividends, shareholding & related party transactions

    • Dividend for FY26: not declared; focus on reinvestment and growth.
    • Promoters hold 54.87%; FPIs 2.79%; Indian public 32.30%; NRIs 7.49%.
    • Related party transactions reported; arm's-length; remuneration to directors disclosed; policy on RPTs.
    • Postal ballot approved appointments of two independent directors (Bedi and Mahajan) on March 28, 2026.

    CSR & ESG

    • CSR expenditure ₹74.30 lakh; 2% average net profit requirement ₹74.30 lakh.
    • One CSR asset created: School building for special children; cost ₹15.75 lakh.
    • ₹30.93 lakh utilized from Unspent CSR account in FY2025-26.

    Subsidiaries & group

    • Kwality Africa Limitada (Mozambique) is 51% owned; turnover and losses modest in year.
    • Group consolidated results include Africa subsidiary; Form AOC-1 disseminates subsidiary details.

    Audit & governance flags

    • Statutory auditors: Vijay Mehra & Co.; no qualifications; term through 2029.
    • Secretarial auditors: Rishi Mittal & Associates; five-year term; no qualifications.
    • Independent Directors meeting held; declarations of independence obtained; compliance with governance norms.
    Read the original filing
  10. Knack Packaging Ltd3:02 am IST

    Knack Packaging Q1 FY27 revenue up 41% YoY; capacity expanded, EBITDA up 53%

    Financial highlights

    • Revenue from operations for Q1 FY27 ₹2,624.59 mn, up 41% YoY.
    • EBITDA ₹591.73 mn, up 53% YoY; margin 22.35%.
    • PAT ₹305.28 mn, up 48% YoY; margin 11.53%.
    • ROCE 54.73%, ROE 37.45% for the quarter.

    Capacity expansion

    • Installed capacity increased from 43,300 to 48,000+ MT per annum.
    • Commissioning of new rented facilities augmented manufacturing capacity.

    Strategic developments

    • On-boarding globally renowned brands in domestic and international markets.
    • Serving 28+ industries with 5–50 kg packaging solutions.
    • Exports to over 74 countries.

    Outlook and management commentary

    • Positive about onboarding global brands; expanding footprint and capabilities.
    • Positioned to respond faster to demand across domestic and international markets.
    Read the original filing